Literature DB >> 26052432

In Vitro Screening of Environmental Chemicals Identifies Zearalenone as a Novel Substrate of the Placental BCRP/ABCG2 Transporter.

Jingcheng Xiao1, Qi Wang2, Kristin M Bircsak2, Xia Wen2, Lauren M Aleksunes3.   

Abstract

The BCRP (ABCG2) transporter is responsible for the efflux of chemicals from the placenta to the maternal circulation. Inhibition of BCRP activity could enhance exposure of offspring to environmental chemicals leading to altered reproductive, endocrine, and metabolic development. The purpose of this study was to characterize environmental chemicals as potential substrates and inhibitors of the human placental BCRP transporter. The interaction of BCRP with a panel of environmental chemicals was assessed using the ATPase and inverted plasma membrane vesicle assays as well as a cell-based fluorescent substrate competition assay. Human HEK cells transfected with wild-type BCRP or the Q141K genetic variant, as well as BeWo placental cells that endogenously express BCRP were used to further test inhibitor and substrate interactions. To varying degrees, the eleven chemicals inhibited BCRP activity in activated ATPase membranes and inverted membrane vesicles. Further, genistein, zearalenone, and tributyltin increased the retention of the fluorescent BCRP substrate, Hoechst 33342, between 50-100% in BeWo cells. Additional experiments characterized the mycotoxin and environmental estrogen, zearalenone, as a novel substrate and inhibitor of BCRP in WT-BCRP and BeWo cells. Interestingly, the BCRP genetic variant Q141K exhibited reduced efflux of zearalenone compared to the wild-type protein. Taken together, screening assays and direct quantification experiments identified zearalenone as a novel human BCRP substrate. Additional in vivo studies are needed to directly determine whether placental BCRP prevents fetal exposure to zearalenone.

Entities:  

Keywords:  ABCG2; BCRP; BeWo; Q141K; genistein; placenta; transporter; tributyltin; zearalenone

Year:  2015        PMID: 26052432      PMCID: PMC4452124          DOI: 10.1039/C4TX00147H

Source DB:  PubMed          Journal:  Toxicol Res (Camb)        ISSN: 2045-452X            Impact factor:   3.524


  60 in total

1.  Single nucleotide polymorphisms modify the transporter activity of ABCG2.

Authors:  Kuniaki Morisaki; Robert W Robey; Csilla Ozvegy-Laczka; Yasumasa Honjo; Orsolya Polgar; Kenneth Steadman; Balázs Sarkadi; Susan E Bates
Journal:  Cancer Chemother Pharmacol       Date:  2005-04-19       Impact factor: 3.333

2.  Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.

Authors:  Robert Elsby; Veronica Smith; Lisa Fox; David Stresser; Caroline Butters; Pradeep Sharma; Dominic D Surry
Journal:  Xenobiotica       Date:  2011-05-25       Impact factor: 1.908

3.  Placental transfer of the estrogenic mycotoxin zearalenone in rats.

Authors:  A Bernhoft; G H Behrens; K Ingebrigtsen; W Langseth; S Berndt; T B Haugen; T Grotmol
Journal:  Reprod Toxicol       Date:  2001 Sep-Oct       Impact factor: 3.143

4.  Late gestational exposure to the fungicide prochloraz delays the onset of parturition and causes reproductive malformations in male but not female rat offspring.

Authors:  Nigel C Noriega; Joseph Ostby; Christy Lambright; Vickie S Wilson; L Earl Gray
Journal:  Biol Reprod       Date:  2005-01-26       Impact factor: 4.285

5.  Expression of members of the multidrug resistance protein family in human term placenta.

Authors:  M V St-Pierre; M A Serrano; R I Macias; U Dubs; M Hoechli; U Lauper; P J Meier; J J Marin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-10       Impact factor: 3.619

6.  Maternal genistein exposure mimics the effects of estrogen on mammary gland development in female mouse offspring.

Authors:  L Hilakivi-Clarke; E Cho; R Clarke
Journal:  Oncol Rep       Date:  1998 May-Jun       Impact factor: 3.906

7.  ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.

Authors:  B Tomlinson; M Hu; V W Y Lee; S S H Lui; T T W Chu; E W M Poon; G T C Ko; L Baum; L S Tam; E K Li
Journal:  Clin Pharmacol Ther       Date:  2010-02-03       Impact factor: 6.875

8.  The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study.

Authors:  Lin Zhou; Suresh Babu Naraharisetti; Honggang Wang; Jashvant D Unadkat; Mary F Hebert; Qingcheng Mao
Journal:  Mol Pharmacol       Date:  2007-12-13       Impact factor: 4.436

9.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

10.  Transgenerational inheritance of increased fat depot size, stem cell reprogramming, and hepatic steatosis elicited by prenatal exposure to the obesogen tributyltin in mice.

Authors:  Raquel Chamorro-García; Margaret Sahu; Rachelle J Abbey; Jhyme Laude; Nhieu Pham; Bruce Blumberg
Journal:  Environ Health Perspect       Date:  2013-01-15       Impact factor: 9.031

View more
  12 in total

Review 1.  Developing novel in vitro methods for the risk assessment of developmental and placental toxicants in the environment.

Authors:  Rebecca C Fry; Jacqueline Bangma; John Szilagyi; Julia E Rager
Journal:  Toxicol Appl Pharmacol       Date:  2019-06-22       Impact factor: 4.219

2.  Placental BCRP/ABCG2 Transporter Prevents Fetal Exposure to the Estrogenic Mycotoxin Zearalenone.

Authors:  John T Szilagyi; Ludwik Gorczyca; Anita Brinker; Brian Buckley; Jeffrey D Laskin; Lauren M Aleksunes
Journal:  Toxicol Sci       Date:  2019-04-01       Impact factor: 4.849

3.  Buprenorphine, Norbuprenorphine, R-Methadone, and S-Methadone Upregulate BCRP/ABCG2 Expression by Activating Aryl Hydrocarbon Receptor in Human Placental Trophoblasts.

Authors:  Naveen K Neradugomma; Michael Z Liao; Qingcheng Mao
Journal:  Mol Pharmacol       Date:  2016-12-14       Impact factor: 4.436

4.  Localization of the placental BCRP/ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity.

Authors:  John T Szilagyi; Anna M Vetrano; Jeffrey D Laskin; Lauren M Aleksunes
Journal:  Placenta       Date:  2017-04-12       Impact factor: 3.481

Review 5.  Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs).

Authors:  Sascha C T Nicklisch; Amro Hamdoun
Journal:  FEBS Lett       Date:  2020-12-09       Impact factor: 4.124

6.  Regulation of the placental BCRP transporter by PPAR gamma.

Authors:  Yixin Lin; Kristin M Bircsak; Ludwik Gorczyca; Xia Wen; Lauren M Aleksunes
Journal:  J Biochem Mol Toxicol       Date:  2016-11-23       Impact factor: 3.642

Review 7.  Review of the environmental prenatal exposome and its relationship to maternal and fetal health.

Authors:  Julia E Rager; Jacqueline Bangma; Celeste Carberry; Alex Chao; Jarod Grossman; Kun Lu; Tracy A Manuck; Jon R Sobus; John Szilagyi; Rebecca C Fry
Journal:  Reprod Toxicol       Date:  2020-02-23       Impact factor: 3.143

8.  Bacillus licheniformis CK1 alleviates the toxic effects of zearalenone in feed on weaned female Tibetan piglets.

Authors:  Guanhua Fu; Lihong Wang; Long Li; Jeruei Liu; Suozhu Liu; Xin Zhao
Journal:  J Anim Sci       Date:  2018-09-29       Impact factor: 3.159

9.  BCRP/ABCG2 Transporter Regulates Accumulation of Cadmium in Kidney Cells: Role of the Q141K Variant in Modulating Nephrotoxicity.

Authors:  Xia Wen; Danielle Kozlosky; Ranran Zhang; Cathleen Doherty; Brian Buckley; Emily Barrett; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2021-06-01       Impact factor: 3.579

10.  Down-regulation of ABCG2 and ABCB4 transporters in the placenta of rats exposed to cadmium.

Authors:  Lili Liu; Liang Zhou; Shuiwang Hu; Shanyu Zhou; Yingyu Deng; Ming Dong; Jianxun Huang; Yuli Zeng; Xiaoyan Chen; Na Zhao; Hongling Li; Zhenhua Ding
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.